BioTelemetry, Inc. (NASDAQ:BEAT) will post its quarterly earnings results on Tuesday, November 7th. Analysts expect BioTelemetry to post earnings of $0.25 per share for the quarter.

BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings results on Tuesday, August 8th. The medical research company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.21 by $0.02. BioTelemetry had a net margin of 21.03% and a return on equity of 18.75%. The business had revenue of $58.10 million for the quarter, compared to analysts’ expectations of $58.39 million. During the same period in the previous year, the company posted $0.20 EPS. BioTelemetry’s revenue was up 10.2% on a year-over-year basis. On average, analysts expect BioTelemetry to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

BioTelemetry, Inc. (BEAT) opened at $28.30 on Friday. The company has a current ratio of 2.03, a quick ratio of 1.91 and a debt-to-equity ratio of 0.16. The firm has a market cap of $915.79, a P/E ratio of 36.28, a price-to-earnings-growth ratio of 1.54 and a beta of 0.58.

Several equities analysts have recently commented on the stock. Zacks Investment Research cut shares of BioTelemetry from a “hold” rating to a “strong sell” rating in a report on Thursday. Raymond James Financial, Inc. assumed coverage on shares of BioTelemetry in a report on Thursday, October 26th. They set an “outperform” rating and a $37.00 price target on the stock. SunTrust Banks, Inc. initiated coverage on shares of BioTelemetry in a report on Monday, October 23rd. They set a “buy” rating and a $41.00 price target on the stock. Off Wall Street initiated coverage on shares of BioTelemetry in a research note on Friday, September 15th. They issued a “sell” rating for the company. Finally, BidaskClub raised shares of BioTelemetry from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 16th. Two investment analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $42.86.

COPYRIGHT VIOLATION WARNING: “BioTelemetry, Inc. (BEAT) to Release Earnings on Tuesday” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at

About BioTelemetry

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Earnings History for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.